MISC - 前田　嘉信

Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice 国際誌

Shoji Asakura, Daigo Hashimoto, Shuichiro Takashima, Haruko Sugiyama, Yoshinobu Maeda, Koichi Akashi, Mitsune Tanimoto, Takanori Teshima

JOURNAL OF CLINICAL INVESTIGATION   120 ( 7 )   2370 - 2378   2010年7月

　詳細を見る

記述言語：英語   出版者・発行元：AMER SOC CLINICAL INVESTIGATION INC  

Allogeneic hematopoietic stem cell transplantation (HSCT) is used effectively to treat a number of hematological malignancies. Its beneficial effects rely on donor-derived T cell-targeted leukemic cells, the so-called graft-versus-leukemia (GVL) effect. Induction of GVL is usually associated with concomitant development of graft-versus-host disease (GVHD), a major complication of allogeneic HSCT. The T cells that mediate GVL and GVHD are activated by alloantigen presented on host antigen-presenting cells of hematopoietic origin, and it is not well understood how alloantigen expression on non-hematopoietic cells affects GVL activity. Here we show, in mouse models of MHC-matched, minor histocompatibility antigen-mismatched bone marrow transplantation, that alloantigen expression on host epithelium drives donor T cells into apoptosis and dysfunction during GVHD, resulting in a loss of GVL activity. During GVHD, programmed death-1 (PD-1) and PD ligand-1 (PD-L1), molecules implicated in inducing T cell exhaustion, were upregulated on activated T cells and the target tissue, respectively, suggesting that the T cell defects driven by host epithelial alloantigen expression might be mediated by the PD-1/PD-L1 pathway. Consistent with this, blockade of PD-1/PD-L1 interactions partially restored T cell effector functions and improved GVL. These results elucidate a previously unrecognized significance of alloantigen expression on non-hematopoietic cells in GVL and suggest that separation of GVL from GVHD for more effective HSCT may be possible in human patients.

DOI： 10.1172/JCI39165

Web of Science

PubMed

researchmap

Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy

D. Ennishi, H. Asai, Y. Maeda, K. Shinagawa, K. Ikeda, M. Yokoyama, Y. Terui, K. Takeuchi, T. Yoshino, K. Matsuo, K. Hatake, M. Tanimoto

ANNALS OF ONCOLOGY   21 ( 6 )   1217 - 1221   2010年6月

　詳細を見る

記述言語：英語   出版者・発行元：OXFORD UNIV PRESS  

Background: A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear.
Patients and methods: We conducted a retrospective study investigating the effects of statins on the prognosis of diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Newly diagnosed DLBCL patients were analyzed (n = 256), including 35 patients taking statins.
Results: The 3-year progression-free survival rates were 84% and 73% (P = 0.38), while the overall survival rates were 89% and 78% (P = 0.28) for those patients treated with and without statins, respectively. After adjusting for the International Prognostic Index and serum cholesterol level, statin use was not associated with prognosis.
Conclusions: These results indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP. Further studies with larger numbers of patients are warranted to confirm the prognostic significance of statins for patients with DLBCL receiving rituximab-containing chemotherapy.

DOI： 10.1093/annonc/mdp490

Web of Science

researchmap

PHASE II STUDY OF SMILE CHEMOTHERAPY FOR NEWLY-DIAGNOSED STAGE IV, RELAPSED OR REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE: NKTSG STUDY

Y. L. Kwong, M. Yamaguchi, Y. Maeda, C. Hashimoto, W. S. Kim, C. W. Suh, E. Sueoka, F. Ishida, K. Izutsu, R. Hyo, S. Nakamura, J. Suzumiya, K. Oshimi, R. Suzuki

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL   95   119 - 120   2010年6月

　詳細を見る

記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：FERRATA STORTI FOUNDATION  

Web of Science

researchmap

Cold agglutinin-induced acrocyanosis in a patient with subclinical chronic lymphocytic leukemia; a beneficial response to rituximab 国際誌

Yoshinori Shirafuji, Yoshinobu Maeda, Keiji Iwatsuki

EUROPEAN JOURNAL OF DERMATOLOGY   20 ( 3 )   394 - 396   2010年5月

　詳細を見る

記述言語：英語   出版者・発行元：JOHN LIBBEY EUROTEXT LTD  

DOI： 10.1684/ejd.2010.0908

Web of Science

PubMed

researchmap

劇症肝炎を発症し、同種造血幹細胞移植を施行したEBV関連NK/T細胞増殖症の2例

新谷 大悟, 近藤 正太郎, 遠西 大輔, 青山 一利, 久保西 四郎, 近藤 英生, 前田 嘉信, 品川 克至, 谷本 光音

日本リンパ網内系学会会誌   50   106 - 106   2010年5月

　詳細を見る

記述言語：日本語   出版者・発行元：(一社)日本リンパ網内系学会  

researchmap

Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: NKTSG study

M. Yamaguchi, Y. Kwong, Y. Maeda, C. Hashimoto, W. Kim, C. Suh, R. Hyo, S. Nakamura, K. Oshimi, R. Suzuki

JOURNAL OF CLINICAL ONCOLOGY   28 ( 15 )   2010年5月

　詳細を見る

記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：AMER SOC CLINICAL ONCOLOGY  

Web of Science

researchmap

Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation: comparison with conventional regimen 国際誌

Kanayo Takahashi, Yoshihiko Soga, Yumeno Murayama, Mika Udagawa, Hitomi Nishimoto, Yuko Sugiura, Yoshinobu Maeda, Mitsune Tanimoto, Shogo Takashiba

SUPPORTIVE CARE IN CANCER   18 ( 1 )   115 - 119   2010年1月

　詳細を見る

記述言語：英語   出版者・発行元：SPRINGER  

Severe oral mucositis induced by allogeneic hematopoietic cell transplantation (HCT) is associated with intolerable pain and risk of systemic bacteremia infection. Differences between conventional HCT and reduced-intensity regimens for allogeneic HCT (RIST) may influence the occurrence and severity of oral mucositis. Here, we evaluated oral mucositis in patients undergoing RIST and compared the results with those in conventional allogeneic HCT patients to facilitate predictive measures for mucositis.
A total of 127 consecutive patients undergoing HCT (conventional, 63; RIST, 64) were included in this study. Severity of oral mucositis during HCT period was evaluated daily. Differences in severity of mucositis among HCT types were analyzed. Use of morphine to control pain due to oral mucositis was evaluated in each HCT method.
The severity of oral mucositis was reduced in patients undergoing RIST. Worsening of oral mucositis was delayed in patients receiving RIST. Use of morphine to control pain due to oral mucositis was significantly decreased in patients undergoing RIST compared with those receiving conventional allogeneic HCT.
The severity of oral mucositis was reduced and the peak day of oral mucositis was delayed in RIST patients compared with those receiving conventional HCT.

DOI： 10.1007/s00520-009-0637-z

Web of Science

PubMed

researchmap

Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation: comparison with conventional regimen

Kanayo Takahashi, Yoshihiko Soga, Yumeno Murayama, Mika Udagawa, Hitomi Nishimoto, Yuko Sugiura, Yoshinobu Maeda, Mitsune Tanimoto, Shogo Takashiba

SUPPORTIVE CARE IN CANCER   18 ( 1 )   115 - 119   2010年1月

　詳細を見る

記述言語：英語   出版者・発行元：SPRINGER  

Severe oral mucositis induced by allogeneic hematopoietic cell transplantation (HCT) is associated with intolerable pain and risk of systemic bacteremia infection. Differences between conventional HCT and reduced-intensity regimens for allogeneic HCT (RIST) may influence the occurrence and severity of oral mucositis. Here, we evaluated oral mucositis in patients undergoing RIST and compared the results with those in conventional allogeneic HCT patients to facilitate predictive measures for mucositis.
A total of 127 consecutive patients undergoing HCT (conventional, 63; RIST, 64) were included in this study. Severity of oral mucositis during HCT period was evaluated daily. Differences in severity of mucositis among HCT types were analyzed. Use of morphine to control pain due to oral mucositis was evaluated in each HCT method.
The severity of oral mucositis was reduced in patients undergoing RIST. Worsening of oral mucositis was delayed in patients receiving RIST. Use of morphine to control pain due to oral mucositis was significantly decreased in patients undergoing RIST compared with those receiving conventional allogeneic HCT.
The severity of oral mucositis was reduced and the peak day of oral mucositis was delayed in RIST patients compared with those receiving conventional HCT.

DOI： 10.1007/s00520-009-0637-z

Web of Science

researchmap

Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer, the Okayama Lung Cancer Study Group experience.

Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Kuyama S, Yonei T, Fujiwara K, Maeda T, Aoe K, Ueoka H, Kamei H, Umemura S, Moritaka T, Segawa Y, Kawai H, Bessho A, Kato K, Tabata M, Tanimoto M

J Thorac Oncol   5 ( 2 )   179 - 184   2010年

　詳細を見る

DOI： 10.1097/JTO.0b013e3181ca12e0

researchmap

Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan.

Itoh K, Kinoshita T, Watanabe T, Yoshimura K, Okamoto R, Chou T, Ogura M, Hirano M, Asaoku H, Kurosawa M, Maeda Y, Omachi K, Moriuchi Y, Kasai M, Ohnishi K, Takayama N, Morishima Y, Tobinai K, Kaba H, Yamamoto S, Fukuda H, Kikuchi M, Yoshino T, Matsuno Y, Hotta T, Shimoyama M

Int J Hematol   91 ( 3 )   446 - 455   2010年

　詳細を見る

DOI： 10.1007/s12185-010-0533-9

researchmap

合成レチノイドAm80によるTh1/Th17を介した慢性GVHD制御

西森久和, 前田嘉信, 杉山暖子, 小林孝一郎, 山筋好子, 近藤英生, 品川克至, 竹内賢吾, 谷本光音

日本造血細胞移植学会総会プログラム・抄録集   32nd   2010年

　詳細を見る

J-GLOBAL

researchmap

Immunoglobulin G4 (IgG4)-positive or -negative ocular adnexal benign lymphoid lesions in relation to systemic involvement

Matsuo T, Ichimura K, Sato Y, Tanimoto Y, Kiura K, Kanazawa S, Okada T, Yoshino T

J Clin Exp Hematop   50 ( 2 )   129 - 142   2010年

　詳細を見る

DOI： 10.3960/jslrt.50.129

researchmap

Incidental Detection of Acute Lymphoblastic Leukemia on [(18)F] Fluorodeoxyglucose Positron Emission Tomography 国際誌

Daisuke Ennishi, Yoshinobu Maeda, Masami Niiya, Katsuji Shinagawa, Mitsune Tanimoto

JOURNAL OF CLINICAL ONCOLOGY   27 ( 36 )   e269 - e270   2009年12月

　詳細を見る

記述言語：英語   出版者・発行元：AMER SOC CLINICAL ONCOLOGY  

DOI： 10.1200/JCO.2009.22.7769

Web of Science

PubMed

researchmap

Prediction of number of apheresis procedures necessary in healthy donors to attain minimally required peripheral blood CD34+cells 国際誌

Noriko Namba, Keitaro Matsuo, Shiro Kubonishi, Tomoko Kikuchi, Yoshinobu Maeda, Masami Niiya, Katsuji Shinagawa, Norio Koide, Kazuma Ikeda, Mitsune Tanimoto

TRANSFUSION   49 ( 11 )   2384 - 2389   2009年11月

　詳細を見る

記述言語：英語   出版者・発行元：WILEY-BLACKWELL  

BACKGROUND:
Allogeneic peripheral blood stem cell (PBSC) transplantation is widely performed as a curative therapy for hematopoietic malignancies. Donors for PBSC harvest (PBSCH) are usually healthy subjects and undergo granulocyte-colony-stimulating factor treatment and apheresis procedures. A considerable proportion of donors experience poor mobilization, necessitating additional harvesting or marrow collection or remobilization. Although some characteristics have been reported to correlate with poor mobilization, they may not be taken into account in selecting PBSC donors. To protect healthy donors, it is preferable to predict the number of apheresis procedures needed for PBSCH before the procedure is initiated.
STUDY DESIGN AND METHODS:
A retrospective cohort study of 83 subjects was conducted, using statistical models to predict the probability of obtaining a sufficient number of CD34+ cells (>= 2.0 x 106/kg) in the first to the third apheresis procedures and the probability of failure to obtain sufficient cells within three apheresis sessions. This study explored potential candidate factors in an ordinal probit regression analysis.
RESULTS:
Significant factors predicting successful PBSCH were donor age, donor sex, and body weight difference between donor and recipient. The predictive model showed good agreement with the observed number of apheresis sessions. Simulation tables are presented with this model.
CONCLUSION:
The statistical model developed to predict the number of apheresis procedures for PBSCH may be useful for planning PBSCH in clinical practice.

DOI： 10.1111/j.1537-2995.2009.02314.x

Web of Science

PubMed

researchmap

Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Peripheral T-Cell Lymphomas (PTCLs): Japan and Korea Cooperative Study with 330 Patients

Sung-Won Kim, Sung-Soo Yoon, Ritsuro Suzuki, Hyeon Gyu Yi, Hiroatsu Ago, Masahiro Imamura, Atsushi Wake, Takashi Yoshida, Je-Jung Lee, Jin Seok Kim, Yoshinobu Maeda, Koji Izutsu, Hye Jin Kang, Je-Hwan Lee, Hugh Chul Kim, Junji Suzumiya, Yoshihiro Matsuno, Chul Woo Kim, Koji Nagafuji, Yoichi Takaue, Mine Harada, Chul Soo Kim

BLOOD   114 ( 22 )   900 - 901   2009年11月

　詳細を見る

記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：AMER SOC HEMATOLOGY  

Web of Science

researchmap

The Impact of Outcome and Hepatic Toxicity in HCV-Infected Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus CHOP Therapy; A Retrospective Multicenter Japanese Analysis.

Daisuke Ennishi, Yoshinobu Maeda, Nozomi Niitsu, Minoru Kojima, Koji Izutsu, Jun Takizawa, Shigeru Kusumoto, Masataka Okamoto, Masahiro Yokoyama, Yasushi Takamatsu, Kazutaka Sunami, Akira Miyata, Kayoko Murayama, Akira Sakai, Morio Matsumoto, Katsuji Shinagawa, Akinobu Takaki, Keitaro Matsuo, Tomohiro Kinoshita, Mitsune Tanimoto

BLOOD   114 ( 22 )   1057 - 1057   2009年11月

　詳細を見る

記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：AMER SOC HEMATOLOGY  

Web of Science

researchmap

Extranodal NK/T-cell lymphoma.nasal type 20症例の単一施設での治療成績

遠西 大輔, 前田 嘉信, 近藤 正太郎, 原 嘉孝, 青山 一利, 大西 尚子, 久保西 四郎, 新谷 勝美, 近藤 英生, 品川 克至, 市村 浩一, 吉野 正, 谷本 光音

臨床血液   50 ( 9 )   996 - 996   2009年9月

　詳細を見る

記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

researchmap

同種造血幹細胞移植を施行した進行期、治療抵抗性extranodal NK/T-cell lymphoma,nasal type 10症例の単一施設での治療成績

遠西 大輔, 前田 嘉信, 品川 克至, 久保西 四郎, 近藤 英生, 新谷 勝美, 市村 浩一, 吉野 正, 谷本 光音

日本リンパ網内系学会会誌   49   119 - 119   2009年6月

　詳細を見る

記述言語：日本語   出版者・発行元：(一社)日本リンパ網内系学会  

researchmap

Clinical Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation for 30 Adults with Hematological Malignancies 国際誌

Koichiro Kobayashi, Yoshinobu Maeda, Yoshitaka Hara, Miyuki Nishie-Kataoka, Hisakazu Nishimori, Haruko Sugiyama, Noriko Namba, Shiro Kubonishi, Masami Niiya, Katsuji Shinagawa, Kazuma Ikeda, Mitsune Tanimoto

ANTICANCER RESEARCH   29 ( 5 )   1763 - 1770   2009年5月

　詳細を見る

記述言語：英語   出版者・発行元：INT INST ANTICANCER RESEARCH  

Background: Umbilical cord blood transplantation (CBT) has increasingly been used as a therapeutic option for adult patients for whom allogeneic stem- cell transplantation is not indicated, due to the availability of cord blood. However, myeloablative conditioning regimens are associated with significant mortality, and high relapse rates in reduced-intensity regimens may result in a poor rate of disease-free survival for those with advanced stages of hematological malignancies. Therefore, it remains unknown whether CBT is a truly effective option for such adults with high-risk disease, as well as for those with standard-risk disease. Patients and Methods: Thirty adult patients with a median age of 45 years (range: 16-67) with standard or high-risk disease underwent CBT from unrelated donors at Okayama University Hospital between October 2002 and May 2007. Twenty-one patients had diseases classified as high-risk for transplantation. The median number of nucleated cells in infused cord blood was 2.65x10(7)/kg (range: 1.73-4.87). Results: Twenty-three patients achieved neutrophil engraftment at a median time of 22 days (range: 13-42) after CBT The cumulative incidence of grade II to IV acute graft-versus-host disease (GVHD) was 53.6%. Out of the 30 patients, I I were alive and disease-free at a median time of 446 days (range: 124-1153) after CBT. The cumulative 1-year overall survival in patients with standard-risk or high-risk disease was 63.5% and 15.4%, respectively (p=0.01). Conclusion: Although from a retrospective study, these results suggest that unrelated donor CBT could be safe and effective for adult patients with standard-risk disease who cannot find a suitable HLA-matched volunteer marrow or peripheral blood donor.

Web of Science

PubMed

researchmap

Febrile neutropenia and periodontitis: lessons from a case periodontal treatment in the intervals between chemotherapy cycles for leukemia reduced febrile neutropenia 国際誌

Yoshihiko Soga, Yoshiko Yamasuji, Chieko Kudo, Kaori Matsuura-Yoshimoto, Kokoro Yamabe, Yuko Sugiura, Yoshinobu Maeda, Fumihiko Ishimaru, Mitsune Tanimoto, Fusanori Nishimura, Shogo Takashiba

SUPPORTIVE CARE IN CANCER   17 ( 5 )   581 - 587   2009年5月

　詳細を見る

記述言語：英語   出版者・発行元：SPRINGER  

Oral and systemic infections arising from the oral cavity are significant problems in clinical management of patients undergoing leukemia treatment. However, there is significant disparity in the reported incidences of development of periodontal infections. Evidence is limited to those showing the systemic influence of periodontal infection in neutropenic patients. This study indicated an association between febrile neutropenia (FN) and periodontitis in a case in which periodontal treatment in the intervals between chemotherapy cycles reduced FN in subsequent courses of chemotherapy and hematopoietic transplantation (HCT).
Periodontal treatment was performed in a 61-year-old man with advanced periodontitis, who received HCT following three cycles of chemotherapy. After recovery from neutropenia induced by initial chemotherapy, periodontal treatment was performed in each chemotherapy interval period. Following extraction of teeth with severe advanced periodontitis, all teeth were subjected to periodontal pocket curettage and root planning, which are common periodontal treatments to reduce periodontal pockets harboring anaerobic periodontal bacteria, before HCT.
Periodontal treatment successfully reduced periodontal pockets from 4.1 +/- 1.5 mm to 3.0 +/- 0.6 mm, which was almost within the healthy range (< 3.0 mm), before HCT. The frequency of FN decreased significantly with increasing cycles of chemotherapy, and decreases in FN corresponded to progress of periodontal treatment. Blood cultures obtained a total of 12 times throughout leukemia treatment were all negative.
The observations reported here indicate the importance of periodontal treatment in clinical management of patients undergoing leukemia treatment to prevent FN, although all blood cultures were negative.

DOI： 10.1007/s00520-008-0532-z

Web of Science

PubMed

researchmap